Centaurus Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Centaurus Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$53K	Hold	17,165	–	–	﹤0.01%	1050
2025 Q4	$70K	Buy	17,165 +400	+2%	+$1.98K	﹤0.01%	1037
2025 Q3	$82K	Buy	16,765 +2,100	+14%	+$11K	﹤0.01%	1026
2025 Q2	$74K	Buy	14,665 +3,555	+32%	+$17.5K	﹤0.01%	955
2025 Q1	$59K	Buy	11,110 +336	+3%	+$2.45K	﹤0.01%	887
2024 Q4	$73K	Hold	10,774	–	–	﹤0.01%	861
2024 Q3	$71K	Buy	+10,774	New	+$77.2K	﹤0.01%	832
2023 Q3	–	Sell	-13,242	Closed	-$99K	–	797
2023 Q2	$99K	Buy	13,242 +2,219	+20%	+$15.5K	0.01%	734
2023 Q1	$74K	Hold	11,023	–	–	0.01%	875
2022 Q4	$85K	Buy	11,023 +1,000	+10%	+$9.81K	0.01%	810
2022 Q3	$107K	Hold	10,023	–	–	0.01%	793
2022 Q2	$82K	Buy	+10,023	New	+$67.1K	0.01%	810

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Centaurus Financial's RXRX Position: Q1 2026 in Review

Centaurus Financial held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 17,165 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #1050.

Centaurus Financial first reported a position in RXRX in Q2 2022 and has held it in 12 quarters since. The position peaked at $107K in Q3 2022. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Centaurus Financial held 17,165 shares of Recursion Pharmaceuticals worth $53K as of Q1 2026.
Centaurus Financial left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Centaurus Financial's portfolio in Q1 2026, its #1050 holding.
Centaurus Financial first reported a position in Recursion Pharmaceuticals in Q2 2022 and has held it in 12 quarters since.
Centaurus Financial's Recursion Pharmaceuticals position peaked at $107K in Q3 2022.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Centaurus Financial's 13F filing for Q1 2026, filed 18 May 2026.